Wird geladen...
Impaired wound healing secondary to bevacizumab
Bevacizumab is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular endothelial growth factor. Consequently, it suppresses endothelial cell proliferation, vascular permeability, and angiogenesis. This inhibitory effect contributes to tumour size reduction but causes wound‐...
Gespeichert in:
| Veröffentlicht in: | Int Wound J |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Blackwell Publishing Ltd
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7948921/ https://ncbi.nlm.nih.gov/pubmed/31111622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/iwj.13139 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|